Literature DB >> 24842301

Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.

Zhaoshi Bao1, Ying Feng2, Hongjun Wang3, Chuanbao Zhang1, Lihua Sun4, Zhuohong Yan2, Qingyang Liu2, Tianzhu Guo2, Mingyang Li1, Xue Yang2, Chuanlu Jiang3, Quangeng Zhang2, Tao Jiang1.   

Abstract

Hypermethylation of tumor suppressor promoters is generally accepted to indicate poor prognosis in glioma; however, the DNA methylation patterns associated with different glioma prognoses remain to be elucidated. In the present study, promoter methylation and gene expression microarrays were used to screen candidate genes between different grades of glioma. Survival analysis was performed using the Kaplan‑Meier (KM) method. Promoter methylation and protein expression of phosphodiesterase 4C (PDE4C) was examined in different grade gliomas and the correlation between PDE4C and wild-type (WT) p53 was evaluated in glioma cell lines. In addition, gene ontology and gene set variation analysis were used to examine PDE4C function. We found PDE4C exhibited promoter hypermethylation in high-grade glioma samples and hypomethylation in low-grade glioma, with PDE4C expression levels showing the reverse. This indicated PDE4C may be a candidate glioma biomarker. Through studies of PDE4C methylation and expression status in an independent cohort of 124 patient samples (56 low-grade and 63 high-grade glioma and 5 normal brain), we identified PDE4C as having significant promoter methylation and lower expression in high-grade glioma. Hypermethylation and reduced PDE4C protein expression were associated with grade progression and overall survival. In glioma cell lines, PDE4C was upregulated by demethylation treatment with 5-Aza-2'-deoxycytidine and WT p53 expression was downregulated after PDE4C siRNA suppression. Finally, we found PDE4C promoted apoptosis and inhibited migration in a U87 cell line. On the basis of these observations and the results from subset analysis, it is reasonable to conclude that PDE4C may function as a tumor suppressor by promoting apoptosis through the WT p53 pathway and inhibiting cell migration. The data show that PDE4C is downregulated through promoter hypermethylation in glioma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24842301     DOI: 10.3892/or.2014.3176

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.

Authors:  Chang Chai; Lai-Jun Song; Shuang-Yin Han; Xi-Qing Li; Ming Li
Journal:  CNS Neurosci Ther       Date:  2018-01-05       Impact factor: 5.243

Review 2.  PDE4 subtypes in cancer.

Authors:  Samuel Hsien Lai; Guston Zervoudakis; Jesse Chou; Mark E Gurney; Kelly M Quesnelle
Journal:  Oncogene       Date:  2020-03-20       Impact factor: 9.867

Review 3.  A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool.

Authors:  Nahid Eskandari; Omid Mirmosayyeb; Gazaleh Bordbari; Reza Bastan; Zahra Yousefi; Alireza Andalib
Journal:  J Res Pharm Pract       Date:  2015 Oct-Dec

4.  A novel strategy for forensic age prediction by DNA methylation and support vector regression model.

Authors:  Cheng Xu; Hongzhu Qu; Guangyu Wang; Bingbing Xie; Yi Shi; Yaran Yang; Zhao Zhao; Lan Hu; Xiangdong Fang; Jiangwei Yan; Lei Feng
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

5.  Methylxanthines: Potential Therapeutic Agents for Glioblastoma.

Authors:  Daniel Pérez-Pérez; Iannel Reyes-Vidal; Elda Georgina Chávez-Cortez; Julio Sotelo; Roxana Magaña-Maldonado
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-07

6.  Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance.

Authors:  Chen Xie; Pen-Jen Lin; Jijun Hao
Journal:  Biomedicines       Date:  2021-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.